New | Cytonics to Begin COVID-19 Treatment Testing

Click to rate this post!
[Total: 0 Your Rating: 0]

Cytonics announces experimental clinical trial to treat COVID-19

Cytonics believes that its lead drug candidate CYT-108, originally designed to stop the breakdown of cartilage in osteoarthritis, may have therapeutic effects in inhibiting inflammation when delivered into the lungs of COVID-19 patients. Because of this, the company decided to create an experimental plan to test its lead drug candidate, CYT-108, as a therapeutic for patients suffering from COVID-19.
Remarkably, the lung inflammation caused by COVID-19 is believed to be caused by the same molecular mechanisms that cause degeneration of cartilage in arthritic joints. Specifically, Cytonics believes that CYT-108 may be able to inhibit the “cytokine storm” that leads to lung inflammation and in some cases, death.
Regarding therapies on the market for COVID-19, the FDA has approved remdesivir and convalescent plasma, but according to many, neither have demonstrated substantial improvement in patient survival. If CYT-108 demonstrates efficacy in bringing down the levels of the SARS-CoV-2 virus and inhibiting cytokines in a preclinical model of COVID-19, Cytonics plans to seek Emergency Use Authorization from the FDA to expedite the drug approval pathway in humans.
“The cure to COVID-19 is unlikely to be found in a single vaccine,” comments Joey Bose, President of Cytonics. “Vaccine development is a costly process fraught with many pitfalls, such as patient attrition, ongoing virus mutation, and limitations on the duration and strength of conferred immunity. We believe that a dual approach that includes clinical treatment of symptoms and anti-viral support in COVID-19 patients is the most effective way to improve patient morbidity and mortality. With this in mind, we are eager to explore developing a therapeutic for COVID-19.”


Join Our Newsletter



By Registering, you agree that you've read and accepted our disclaimer, you're at least 18 years old, you consent to the terms presented on the disclaimer, and to receive notifications from us.